Saturday 17 October 2026
Export NYXH’s income statement to Excel — free account
Nyxoah SA
NYXH Healthcare Medical Instruments & Supplies
Nyxoah SA’s revenue for fiscal 2025 (year ended December 2025) was $11.3 million, up 131.7% from fiscal 2024. In the quarter to June 2026, revenue grew 486.6%, EPS fell 6.35%, free cash flow grew 4.01% and total debt rose 185.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
1.11
0.08
−6.72%
Follow NYXH
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.84 | 7.14 | 15.46 | 27.99 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.04) | (5.00) | (10.46) | (8.10) | |
P/B ratio |
1.00 | 3.01 | 3.15 | 3.07 | |
Price to Tangible BV |
2.36 | 0.00 | 0.00 | 185.17 | |
EV/Sales |
2.06 | 7.77 | 14.79 | 27.62 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.63) | (1.64) | (2.15) | (2.30) | |
EV/FCF |
(0.60) | (1.57) | (2.04) | (2.17) | |
Quick Ratio |
2.29 | 0.85 | 1.13 | 1.29 | |
Current Ratio |
2.38 | 0.99 | 1.25 | 1.70 | |
Net Debt/EBITDA |
2.04 | (0.50) | 0.35 | 0.09 | |
Debt/Assets |
35.28% | 36.23% | 34.86% | 21.81% | |
Debt/Equity |
0.72 | 0.99 | 0.84 | 0.40 | |
Asset Turnover |
0.15 | 0.14 | 0.07 | 0.05 | |
Operating CF/Net income |
0.50 | 1.35 | 0.58 | 0.82 | |
Capex/Depreciation |
(0.96) | (0.25) | (0.82) | (0.11) | |
Interest Coverage |
(1.57) | (10.07) | (5.66) | (41.80) | |
Research and Development Expense of Revenue |
124.34% | 138.17% | 204.80% | 654.72% | |
Selling, General and Administrative Expense of Revenue |
203.49% | 241.27% | 236.98% | 644.12% | |
Intangible Assets out of Total Assets |
0.29 | 0.50 | 0.42 | 0.54 | |
Share Based Compensation of Revenue |
20.26% | 13.83% | 17.60% | 52.25% | |
Graham Net Nets |
0.33 | (0.20) | (0.05) | (0.05) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(149.11%) | (84.93%) | (58.26%) | (54.13%) | |
Free Cash Flow Yield |
(89.78%) | (69.22%) | (46.95%) | (45.41%) | |
Revenue per Share |
0.16 | 0.17 | 0.17 | 0.06 | |
Operating CF per Share |
(0.34) | (0.58) | (0.44) | (0.57) | |
Capex per Share |
(0.04) | (0.01) | (0.04) | 0.00 | |
Free Cash Flow per Share |
(0.37) | (0.60) | (0.48) | (0.57) | |
Cash per Share |
1.99 | 0.70 | 1.43 | 0.66 | |
Shareholders Equity per Share |
1.69 | 0.97 | 1.46 | 1.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.69 | 0.97 | 1.46 | 1.50 | |
Free Cash Flow |
(21.12) | (25.73) | (18.22) | (21.43) | |
Working Capital |
76.05 | (0.57) | 13.87 | 16.04 | |
Capital Expenditures |
(2.02) | (0.50) | (1.47) | (0.16) | |
Net Current Asset Value |
31.76 | (24.77) | (9.20) | (8.03) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.23 | 0.07 | 0.23 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
8.44 | 8.27 | 7.55 | 5.43 | |
Average Payables |
12.69 | 12.30 | 12.91 | 9.16 | |
Average Inventory |
5.18 | 5.17 | 5.19 | 6.24 | |
Average Assets |
164.05 | 128.70 | 152.72 | 129.95 | |
Average Common Equity |
89.98 | 69.90 | 89.07 | 85.58 |
Columns are period end dates